Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 5, 2013, Pages 1405-1415

  Aydin, R Seda Tiǧli ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

drug delivery; herceptin; nanoparticles; salinomycin; targeting

Indexed keywords

CHEMOTHERAPEUTIC DRUGS; DRUG-DELIVERY SYSTEMS; HERCEPTIN; NANOPARTICULATE SYSTEM; PLGA NANOPARTICLES; POLY(LACTIC-CO-GLYCOLIC ACID); SALINOMYCIN; TARGETING;

COPOLYMERS; DISEASES; DRUG DELIVERY; ENCAPSULATION; FLOW CYTOMETRY; ONCOLOGY; OPTICAL MICROSCOPY; PARTICLE SIZE; STEM CELLS; SURFACE CHEMISTRY;

NANOPARTICLES;

NANOPARTICLE; POLYGLACTIN; SALINOMYCIN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; PARTICLE SIZE; X RAY DIFFRACTION;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID; PYRANS; RECEPTOR, ERBB-2;

EID: 84884211845     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34448     Document Type: Article

References (44)

1. Vargo-Gogola T, Rosen JM,. Modeling breast cancer: One size does not fit all. Nat Rev Cancer 2007; 7: 659-672.
2. Hathaway HJ, Butler KS, Adolphi NL, Lovato DM, Belfon R, Fegan D, Monson TC, Trujillo JE, Tessier TE, Bryant HC, Huber DL, Larson RS, Flynn ER,. Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors. Breast Cancer Res 2011; 13: 1-13.
3. Friedland D, Gorman G, Treat J,. Hypersensitivity reactions from taxol and etoposide. J Natl Cancer Inst 1993; 85: 2036.
4. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV,. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102: 1003-1009.
5. Leroux JC, Doelker E, Gurny R,. The use of drug-loaded nanoparticles in cancer chemotherapy. In:, Benita S, editor. Microencapsulation: Methods and Industrial Applications. New York: Marcel Dekker; 1996. p 535-575.
6. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F, Jain RK,. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999; 59: 4129-4135.
7. Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R,. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751-760.
8. El-Dakdouki MH, Zhu DC, El-Boubbou K, Kamat M, Chen J, Li W, Huang X,. Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. Biomacromolecules 2012; 13: 1144-1151.
9. Sunoqrot S, Bae JW, Pearson RM, Shyu K, Liu Y, Kim D-H, Hong S,. Temporal control over cellular targeting through hybridization of folate-targeted dendrimers and PEG-PLA nanoparticles. Biomacromolecules 2012; 13: 1223-1230.
10. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer R, Farokhzad OC,. Targeted nanoparticles for cancer therapy. Nano Today 2007; 2: 14-21.
11. Zhao J, Mi Y, Liu Y, Feng S-S,. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials 2012; 33: 1948-1958.
12. Fonseca C, Simoás S, Gaspara R,. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002; 83: 273-286.
13. Gao J, Kou G, Wang H, Chen H, Li B, Lu Y, Zhang D, Wang S, Hou S, Qian W, Dai J, Zhao J, Zhong Y, Guo Y,. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res Treat 2009; 115: 29-41.
14. Bojat V, Balabanyan V, Alyautdin R,. The entrapment of paclitaxel in PLGA nanoparticles increases its cytotoxicity against multiresistant cell line. Brit J Med Med Res 2011; 1; 306-319.
15. Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, Kreuter J,. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS ONE 2011; 6: e19121.
16. Feng SS, Huang GF,. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J Control Release 2001; 71: 53-69.
17. Koziara JM, Lockman PR, Allen DD, Mumper RJ,. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004; 99: 259-269.
18. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J,. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur J Pharm Biopharm 2010; 74: 157-163.
19. Yang J, Lee C-H, Park J, Seo S, Lim E-K, Song YJ, Suh JS, Yoon HG, Huh YM, Haam S,. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 2007; 17: 2695-2699.
20. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J,. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007; 120: 18-26.
21. Dhankar R, Rathee P, Jain AK, Arora S, Kumar MS, Rath G, Saxena AK, Sharma PR, Chashoo G, Goyal AK,. HER-2 targeted immunonanoparticles for breast cancer chemotherapy. J Appl Pharm Sci 2011; 1: 132-139.
22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L,. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
23. Hudis CA,. Drug therapy: Trastuzumab-Mechanism of action and use in clinical practice. New Engl J Med 2007; 357: 39-51.
24. Muller V, Witzel I, Stickeler E,. Immunological approaches in the treatment of metastasized breast cancer. Breast Care 2009; 4: 358-366.
25. Senter PD,. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009; 13: 235-244.
26. Sun B, Ranganathan B, Feng S-S,. Multifunctional poly(D,L -lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008; 29: 475-486.
27. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC,. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. JNCI 2008; 100: 672-679.
28. Stingl J, Caldas C,. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 7: 791-799.
29. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
30. Eyler CE, Rich JN,. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-2845.
31. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C,. Salinomycin, a new polyether antibiotic. J Antibiot 1974; 27: 814-821.
32. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander AS,. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
33. Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q,. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012; 33: 679-691.
34. Dirks P,. Cancer stem cells: Invitation to a second round. Nature 2010; 466: 40-41.
35. The TH, Feltkamp TEW,. Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. Immunology 1970; 8: 875-881.
36. Liu YT, Li K, Liu B, Feng SS,. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010; 31: 9145-9155.
37. Win KY, Feng SS,. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713-2722.
38. Gõmez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E,. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007; 331: 153-159.
39. Mainardes RM, Gremião MPD, Evangelista RC,. Thermoanalytical study of praziquantel-loaded PLGA nanoparticles. B J Pharm Sci 2006; 42: 523-530.
40. Sun B, Rachmawati H, Feng S-S,. Antibody-conjugated nanoparticles of biodegradable polymers for targeted drug delivery In:, Reisner DE, editor. Bionanotechnology. II. Global Prospects. Farmington, Connecticut: CRC Press; 2011. p 155-80.
41. Decuzzi P, Ferrari M,. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007; 28: 2915-2922.
42. Moasser MM,. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007; 26: 6577-6592.
43. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H,. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin. Nanoparticles Bioconjugate Chem 2008; 19: 2321-2331.
44. Jain RK, Stylianopoulos T,. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7: 653-664.